B
BAROnova
Clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss
About BAROnova
BAROnova is a clinical-stage medical device company that has developed a non-surgical and non-pharmacologic device to induce weight loss. The company's flagship product, the TransPyloric Shuttle (TPS), is designed to be a safe, effective, and reversible solution for obesity. The TPS is delivered and retrieved endoscopically, a minimally invasive procedure, and works by creating a feeling of fullness, which helps patients to eat less and, consequently, lose weight. The device is positioned in the stomach to hold the pylorus, the valve that controls the emptying of the stomach, in an open position. This allows food to pass into the small intestine more quickly, which is believed to trigger hormonal signals that lead to early satiety.
Read full description
The company targets the large and growing market of individuals struggling with obesity who are seeking alternatives to more invasive surgical procedures like gastric bypass or sleeve gastrectomy. BAROnova's business model is focused on the development and commercialization of its proprietary medical devices. The company generates revenue through the sale of the TransPyloric Shuttle to hospitals and clinics that specialize in weight management and gastroenterology.
At a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Goleta, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 30.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning BAROnova.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Sep 2016 | $7.5M | — | Square 1 Bank | — |
| SERIES DOther financing | Nov 2015 | $37M | $146M | Longitude Capital · Delos Capital | — |
Growth signals
Latest recorded traffic for BAROnova is 270 monthly website visits, down 98.2% over the last three months. BAROnova's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Highland Capital Partners
Arboretum Ventures- OVOnset Ventures
Allergan
Series B and later7 investors entered at this stage
- PNPneumRx
Boston Scientific
Sante Ventures
Lumira Ventures
Longitude Capital
Delos Capital
Square 1 Bank
Other known investors1 additional known investor
Duke University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BAROnova on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BAROnova’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.